Cargando…

Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections

There is great interest in passive transfer of broadly neutralizing antibodies (bnAbs) and engineered bispecific antibodies (Abs) for prevention of HIV-1 infections due to their in vitro neutralization breadth and potency against global isolates and long in vivo half-lives. We compared the potential...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wagh, Kshitij, Seaman, Michael S., Zingg, Marshall, Fitzsimons, Tomas, Barouch, Dan H., Burton, Dennis R., Connors, Mark, Ho, David D., Mascola, John R., Nussenzweig, Michel C., Ravetch, Jeffrey, Gautam, Rajeev, Martin, Malcolm A., Montefiori, David C., Korber, Bette
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5854441/ https://www.ncbi.nlm.nih.gov/pubmed/29505593 http://dx.doi.org/10.1371/journal.ppat.1006860

Ejemplares similares

Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection
por: Wagh, Kshitij, et al.
Publicado: (2016)

A single, continuous metric to define tiered serum neutralization potency against HIV
por: Hraber, Peter, et al.
Publicado: (2018)

Divide and conquer: broadly neutralizing antibody combinations for improved HIV-1 viral coverage
por: Wagh, Kshitij, et al.
Publicado: (2023)

Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies
por: Haynes, Barton F., et al.
Publicado: (2022)

Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments
por: Hraber, Peter, et al.
Publicado: (2017)

Genetic Signatures in the Envelope Glycoproteins of HIV-1 that Associate with Broadly Neutralizing Antibodies
por: Gnanakaran, S., et al.
Publicado: (2010)

Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells
por: Cohen, Yehuda Z., et al.
Publicado: (2018)

Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models
por: Lacerda, Miguel, et al.
Publicado: (2013)

Polyvalent vaccine approaches to combat HIV‐1 diversity
por: Korber, Bette, et al.
Publicado: (2017)

Editorial: Novel Concepts in Using Broadly Neutralizing Antibodies for HIV-1 Treatment and Prevention
por: Wagh, Kshitij, et al.
Publicado: (2021)

Bispecific Anti-HIV Immunoadhesins That Bind Gp120 and Gp41 Have Broad and Potent HIV-Neutralizing Activity
por: Pincus, Seth H., et al.
Publicado: (2021)

Combinations of Single Chain Variable Fragments From HIV Broadly Neutralizing Antibodies Demonstrate High Potency and Breadth
por: van Dorsten, Rebecca T., et al.
Publicado: (2021)

Broadly neutralizing monoclonal antibodies for HIV prevention
por: Miner, Maurine D., et al.
Publicado: (2021)

Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations
por: Han, Qifeng, et al.
Publicado: (2019)

Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial
por: Julg, Boris, et al.
Publicado: (2022)

Broadly Neutralizing Antibodies for HIV Eradication
por: Stephenson, Kathryn E., et al.
Publicado: (2016)

Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques
por: Shingai, Masashi, et al.
Publicado: (2014)

Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01
por: Pinto, Dora, et al.
Publicado: (2019)

A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch
por: Wang, Zijun, et al.
Publicado: (2020)

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines
por: Shen, Xiaoying, et al.
Publicado: (2021)

Stability and neutralization capacity of a novel mosaic HIV-1 gp140 trimer in a guinea pig model
por: Nkolola, JP, et al.
Publicado: (2012)

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines
por: Shen, Xiaoying, et al.
Publicado: (2021)

Development of a bispecific nanobody conjugate broadly neutralizes diverse SARS-CoV-2 variants and structural basis for its broad neutralization
por: Yang, Jing, et al.
Publicado: (2023)

Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope
por: Schoofs, Till, et al.
Publicado: (2019)

Broadly Neutralizing Antibodies for HIV-1 Prevention
por: Walsh, Stephen R., et al.
Publicado: (2021)

Computational Prediction of Broadly Neutralizing HIV-1 Antibody Epitopes from Neutralization Activity Data
por: Ferguson, Andrew L., et al.
Publicado: (2013)

Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351
por: Shen, Xiaoying, et al.
Publicado: (2021)

Effects of Darwinian Selection and Mutability on Rate of Broadly Neutralizing Antibody Evolution during HIV-1 Infection
por: Sheng, Zizhang, et al.
Publicado: (2016)

Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody
por: Li, Cheng, et al.
Publicado: (2022)

Neutralization tiers of HIV-1
por: Montefiori, David C., et al.
Publicado: (2018)

Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Primary African Isolates
por: Lorenzi, Julio C. C., et al.
Publicado: (2021)

Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies
por: LaBranche, Celia C., et al.
Publicado: (2019)

Correction: Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies
por: LaBranche, Celia C., et al.
Publicado: (2019)

HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design
por: Bricault, Christine A., et al.
Publicado: (2019)

HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design
por: Bricault, Christine A., et al.
Publicado: (2019)

Implementation of a three-tiered approach to identify and characterize anti-drug antibodies raised against HIV-specific broadly neutralizing antibodies
por: Bharadwaj, Pranay, et al.
Publicado: (2020)

Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates
por: Cai, Fangping, et al.
Publicado: (2021)

Durable protection against repeated penile exposures to simian-human immunodeficiency virus by broadly neutralizing antibodies
por: Garber, David A., et al.
Publicado: (2020)

Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies
por: McCoy, Laura E., et al.
Publicado: (2015)

Pharmacokinetics and Immunogenicity of Broadly Neutralizing HIV Monoclonal Antibodies in Macaques
por: Rosenberg, Yvonne, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_qpfgvbd5do3s9q6k5mg6gk3bms